Abstract 2927
Background
Cancer, which is included in the scope of chronic diseases, affects the lifestyle and quality of the individuals, who got diagnosed, and their familes due to the disease course and treatment method. According to the "theory of family systems", when a disease occurs in the individual, the whole family is affected by the disease, not only patient. It is suggested that families should not be seen as a passive shelter for patients, they should also as a human unity living at the same time as the cancer crisis. In cancer care, caregivers have many responsibilities, from diagnosis to the end of life. While there are studies conducted to evaluate the quality of life of cancer patients in Turkey and other countries, there are a limited number of studies evaluating the quality of life of caregivers of cancer patients. It was aimed to performed in our country for validity and reliability of "Singapore Caregiver Quality Of Life Scale", which was planned based on this deficiency, and to be a guide for the evaluation of the quality of the life of the relatives or carers of different cultures, different ethnic groups and determining the nursing care strategies.
Methods
This study, which was planned as a methodological and descriptive study, was caried out with 550 caregivers in two university hospitals in Izmir. The data were collected by using the Individual Presentation Form, Singapore Caregiver Quality of Life Scale and Quality of Life Scale in Cancer Patients Family Version. Written informed consent was obtained from hospitals and individuals.
Results
The analysis of the findings is ongoing and will be shared in the full text.
Conclusions
Quality of life of caregivers of cancer patients is an important indicator of the quality of life of the patient. In this study, Turkish validation sfudies of the "Singapore Caregiver Quality Of Life Scale" were conducted. The results will be shared later.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract